MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
71.33
+0.33
+0.46%
After Hours: 72.99 +1.66 +2.33% 19:59 02/13 EST
OPEN
70.48
PREV CLOSE
71.00
HIGH
73.37
LOW
67.70
VOLUME
2.27M
TURNOVER
--
52 WEEK HIGH
73.37
52 WEEK LOW
6.48
MARKET CAP
1.45B
P/E (TTM)
-8.9989
1D
5D
1M
3M
1Y
5Y
1D
Nektar Therapeutics Prices $400 Million Offering of Shares and Pre-Funded Warrants
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Iron Mountain, BridgeBio, Old Dominion, 
Reuters · 1d ago
BUZZ-Nektar Therapeutics eases after boosted $400 mln share sale
Reuters · 1d ago
Nektar 6.6M share Secondary priced at $58.00
TipRanks · 2d ago
Reported Earlier, Nektar Therapeutics Prices Upsized $400M Public Offering Of 6,603,449 Common Shares At $58.00 Per Share Price
Benzinga · 2d ago
Nektar Therapeutics prices $400M stock offering
Seeking Alpha · 2d ago
*Nektar Therapeutics Expects Offering to Close Feb. 13 >NKTR
Dow Jones · 2d ago
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.